Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Concurrent treatment of aplastic anemia/Paroxysmal Nocturnal Hemoglobinuria syndrome with immunosuppressive therapy and eculizumab: a UK experience

    Journal Title:  Haematologica Primary Author:  Griffin M Author(s):  Griffin ...

    Research Article last updated 04/11/2018 - 10:05am.

  2. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

    ... hemolysis , effectively controlled with eculizumab , a humanized monoclonal antibody that binds complement ... data, hemolysis biomarkers, complement assessment and free eculizumab circulating levels were systematically measured immediately prior ...

    Research Article last updated 01/20/2015 - 2:28pm.

  3. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria

    ... BACKGROUND: Eculizumab , a humanized monoclonal antibody against complement ... of life and overall survival, but data on the use of eculizumab in women during pregnancy are scarce. METHODS: We ...

    Research Article last updated 10/12/2015 - 10:05am.

  4. Polymorphism of the complement receptor 1 gene correlates with hematological response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria

    ... Complement blockade by eculizumab is clinically effective in hemolytic Paroxysmal Nocturnal ... with hemolytic Paroxysmal Nocturnal Hemoglobinuria on eculizumab we tested the hypothesis that response may depend on genetic ...

    Research Article last updated 09/26/2013 - 3:28pm.

  5. Eculizumab

    Eculizumab (Soliris ®) is given as an IV into a vein at the doctor’s ... Some common side effects of eculizumab include: Headache Tiredness Nausea and vomiting ...

    Topic section last updated 03/29/2016 - 7:20pm.

  6. Knowing What it Takes

    ... I had to face how this disease affected me. I started eculizumab (Soliris®) and my blood counts stabilized, but remained ...

    Patient Chronicle last updated 04/26/2018 - 12:46pm.

  7. Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria

    ... Therapeutic complement inhibition by eculizumab has revolutionized the treatment of paroxysmal nocturnal ... agents seem to recapitulate safety and efficacy of current eculizumab treatment; their main improvement pertains to better patient's ...

    Research Article last updated 04/11/2018 - 10:54am.

  8. A Story of Hope

    ... regularly sees her local hematologist.  “Soliris ® ( eculizumab ) has been a life-changer,” she said.  “Things are so much ...

    Patient Chronicle last updated 04/26/2018 - 10:39am.

  9. Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis

    Journal Title:  Bone Marrow Transplant Primary Author:  Pagliuca S Author(s):  ...

    Research Article last updated 12/06/2017 - 8:46am.

  10. Long term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.

    ... due to intense intravascular hemolysis . Eculizumab , a monoclonal antibody against the complement protein ... in PNH. We evaluated 79 consecutive patients treated with eculizumab in Leeds between May 2002 and July 2010. Mortality and disease ...

    Research Article last updated 10/11/2011 - 5:58pm.